Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+/R- solid organ transplant recipients

Transplant Infectious Disease

Volumn 17, Issue 5, 2015, Pages 637-646

  San Juan, R ^a   Navarro, D ^b   Garcia Reyne A ^a   Montejo, M ^c   Munoz P ^d   Carratala, J ^e   Len, O ^f   Fortun, J ^g   Munoz Cobo B ^b   Gimenez, E ^b   Eworo, A ^d   Sabe, N ^e   Meije, Y ^f   Martin Davila P ^g   Andres, A ^a   Delgado, J ^a   Jimenez, C ^a   Amat, P ^b   Fernandez Ruiz M ^a   Lopez Medrano F ^a   Lumbreras, C ^a   Aguado, J M ^a   more..

^a Universidad Complutense ^*  (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c HOSPITAL DE CRUCES   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

CMV specific cell mediated immunity; D+ R ; Long term prophylaxis; Solid organ transplantation

Indexed keywords

ANTIVIRUS AGENT; CD69 ANTIGEN; CYTOMEGALOVIRUS ANTIGEN PP65; GAMMA INTERFERON; GANCICLOVIR; VALGANCICLOVIR;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; GRAFT RECIPIENT; HEART GRAFT; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION PREVENTION; KIDNEY GRAFT; LIVER GRAFT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; TREATMENT RESPONSE; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTIONS; FOLLOW UP; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; PROCEDURES; PROSPECTIVE STUDY; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; GANCICLOVIR; HUMANS; IMMUNITY, CELLULAR; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84943198850     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12417     Document Type: Article

References (27)

1. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4 (4): 611-620.
2. Kletzmayr J, Kreuzwieser E, Watkins-Riedel T, Berlakovich G, Kovarik J, Klauser R. Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients. Transplantation 2000; 70 (8): 1174-1180.
3. San Juan R, Aguado JM, Diaz-Pedroche C, et al. A review of critical periods for opportunistic infection in the new transplantation era. Transplantation 2006; 82 (11): 1457-1462.
4. Limaye AP, Bakthavatsalam R, Kim HW, et al. Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 2004; 78 (9): 1390-1396.
5. Akalin E, Sehgal V, Ames S, et al. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 2003; 3 (6): 731-735.
6. Limaye AP, Bakthavatsalam R, Kim HW, et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006; 81 (12): 1645-1652.
7. Humar A, Limaye AP, Blumberg EA, et al. Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation 2010; 90 (12): 1427-1431.
8. Gerna G, Lilleri D, Chiesa A, et al. Virologic and immunologic monitoring of cytomegalovirus to guide preemptive therapy in solid-organ transplantation. Am J Transplant 2011; 11 (11): 2463-2471.
9. Kumar D, Chernenko S, Moussa G, et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 2009; 9 (5): 1214-1222.
10. Manuel O, Husain S, Kumar D, et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis 2013; 56 (6): 817-824.
11. Humar A, Mazzulli T, Moussa G, et al. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients. Am J Transplant 2005; 5 (5): 1065-1070.
12. Sester M, Gartner BC, Sester U, Girndt M, Mueller-Lantzsch N, Kohler H. Is the cytomegalovirus serologic status always accurate? A comparative analysis of humoral and cellular immunity. Transplantation 2003; 76 (8): 1229-1230.
13. The TH, van der Ploeg M, van den Berg AP, Vlieger AM, van der Giessen M, van Son WJ. Direct detection of cytomegalovirus in peripheral blood leukocytes - a review of the antigenemia assay and polymerase chain reaction. Transplantation 1992; 54 (2): 193-198.
14. Kearns AM, Guiver M, James V, King J. Development and evaluation of a real-time quantitative PCR for the detection of human cytomegalovirus. J Virol Methods 2001; 95 (1-2): 121-131.
15. de la Torre-Cisneros J, Farinas MC, Caston JJ, et al. GESITRASEIMC/ REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients. Enferm Infecc Microbiol Clin 2011; 29 (10): 735-758.
16. Kern F, Faulhaber N, Frommel C, et al. Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur J Immunol 2000; 30 (6): 1676-1682.
17. Solano C, Benet I, Clari MA, et al. Enumeration of cytomegalovirus-specific interferon gamma CD8+ and CD4+ T cells early after allogeneic stem cell transplantation may identify patients at risk of active cytomegalovirus infection. Haematologica 2008; 93 (9): 1434-1436.
18. Benmarzouk-Hidalgo OJ, Cisneros JM, Cordero E, et al. Therapeutic effect of the acquisition of cytomegalovirus-specific immune response during preemptive treatment. Transplantation 2011; 91 (8): 927-933.
19. Abate D, Saldan A, Fiscon M, et al. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMVspecific T cell reconstitution in kidney transplant recipients. J Infect Dis 2010; 202 (4): 585-594.
20. Snyder LD, Medinas R, Chan C, et al. Polyfunctional cytomegalovirus-specific immunity in lung transplant recipients receiving valganciclovir prophylaxis. Am J Transplant 2012; 11 (3): 553-560.
21. La Rosa C, Limaye AP, Krishnan A, Blumstein G, Longmate J, Diamond DJ. Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients. Transpl Int 2011; 24 (9): 920-931.
22. Bestard O, Lucia M, Crespo E, et al. Pretransplant immediately early-1-specific T cell responses provide protection for CMV infection after kidney transplantation. Am J Transplant 2013; 13 (7): 1793-1805.
23. Lucia M, Crespo E, Melilli E, et al. Preformed frequencies of cytomegalovirus (CMV)-specific memory T and B cells identify protected CMV-sensitized individuals among seronegative kidney transplant recipients. Clin Infect Dis 2014; 59 (11): 1537-1545.
24. Cantisan S, Lara R, Montejo M, et al. Pretransplant interferongamma secretion by CMV-specific CD8+ T cells informs the risk of CMV replication after transplantation. Am J Transplant 2013; 13 (3): 738-745.
25. Egli A, Humar A, Kumar D. State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician. Clin Infect Dis 2012; 55 (12): 1678-1689.
26. Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005; 202 (5): 673-685.
27. Gimeno C, Solano C, Latorre JC, et al. Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients. J Clin Microbiol 2008; 46 (10): 3311-3318.